Stock Price & Analysis

Based on the provided data and recent market activity, here's a concise analysis of BSX stock:

Technical Analysis

The stock closed at $104.49 on February 21, 2025, showing a slight decline of 0.83% from the previous day. The stock has been trading in a strong upward trend over the past year, with significant momentum.

Fundamental Strengths

• Strong Geographic Expansion: BSX continues to show robust growth in emerging markets and EMEA region, particularly in Electrophysiology and Structural Heart segments.

• Strategic Acquisitions: Recent notable acquisitions include:

  • Silk Road Medical ($1.16B) - June 2024
  • Axonics ($3.7B) - January 2024
  • Apollo Endosurgery and Relievant Medsystems - 2023

Analyst Consensus

Based on 19 analysts covering BSX:

• Strong Buy: 14 analysts (73.68%)
• Buy: 4 analysts (21.05%)
• Hold: 1 analyst (5.26%)
• Average price target: $110.05 (5.32% upside)
• Highest target: $130.00 (24.41% upside)

Growth Outlook

• Expected EPS growth of 13.2% in 2024
• Consistent earnings beats in the last four quarters with an average surprise of 7.5%
• Strong momentum in core business segments and international markets

Recommendation

Based on the combination of strong technical momentum, solid fundamentals, and positive analyst sentiment, BSX stock appears to be a BUY at current levels. The company's strategic acquisitions and geographic expansion provide multiple growth catalysts, while consistent earnings beats demonstrate operational execution.

Based on the provided data and recent analyst reports, here is the price prediction for BSX stock in 2025:

Technical Analysis

Price Target Analysis BSX is expected to reach $108-119 by end of 2025 based on the following factors:

• Recent analyst consensus shows strong bullish sentiment with 24 "Strong Buys" out of 27 analysts covering the stock
• Raymond James raised their price target to $119 in January 2025, citing BSX's position as one of the most dynamic players in MedTech sector
• The mean analyst price target is $103.74 with a high target of $113, suggesting 10.4% upside potential from current levels

Key Growth Drivers

• Strong financial performance with expected EPS growth of 20% to $2.46 in FY2024
• Strategic acquisitions like Bolt Medical ($900M deal) enhancing cardiovascular portfolio
• Consistent earnings beats in last four quarters demonstrating execution strength

The stock is likely to reach $108-110 by mid-2025 and potentially test $115-119 levels by year-end 2025, supported by continued business momentum and positive analyst sentiment. The primary catalyst will be sustained earnings growth and successful integration of strategic acquisitions.

The S1 support level for BSX Stock is $99.1 ,The R1 resistant level for BSX Stock is $106.46.

As of the end of day on 2025-02-27, the price of BSX Stock was $101.07.

The target price for BSX Stock according to analyst rating is 118.95, with the highest price target at 135.00 and the lowest at 100.00. Analysts have a Strong Buy rating on BSX Stock overall.

The market cap of BSX is $149.9B.

Based on the comprehensive data analysis, BSX appears to be fairly valued at current levels. Here's why:

Valuation Metrics

• P/E ratio has significantly improved from 103.76 in 2022 to 53.89 in 2023, showing better earnings efficiency
• EV/EBITDA of 25.71 is slightly elevated compared to 2022's 23.16
• Current price of $104.49 is trading near analysts' average target of $103.74

Growth & Profitability

• Revenue grew 12.3% YoY to $14.24B in 2023
• Net income increased substantially by 144.5% to $1.57B
• Gross margin improved to 63.83% from 62.66%
• ROE more than doubled to 8.52% from 3.75%

Technical Analysis

• RSI-14 at 63.45 indicates moderate bullish momentum without being overbought
• Trading above all major moving averages (SMA 20/60/200)
• Currently near the upper Bollinger Band ($108.86), suggesting limited immediate upside

Analyst Consensus

• Strong bullish sentiment with 24 "Strong Buys" out of 27 analysts
• Recent price target raise by Raymond James to $119, citing BSX as one of the most dynamic MedTech players
• However, current price has already reached most analysts' targets

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company’s segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. The Cardiovascular segment includes Cardiology and Peripheral Interventions. The Company's Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions.

Based on the provided data and analyst reports, Boston Scientific (BSX) stock is projected to reach $165-175 by 2030, driven by its strong market position in medical devices and consistent revenue growth of 15-20% annually. The company's strategic acquisitions like Bolt Medical and expansion in cardiovascular portfolio position it well for long-term growth. Multiple analysts maintain "Strong Buy" ratings with increasing price targets, with Raymond James setting the highest near-term target of $119, indicating strong momentum and market confidence in BSX's growth trajectory.

BSX has a total of 48000 employees.